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Dear Sirs,
Central nervous system (CNS) recurrence of systemic
aggressive B-cell lymphoma carries poor prognosis with
median survival of 2–4 months and less than 10% 1-year
survival after treatment with standard-dose chemotherapy
and/or radiotherapy [1, 2]. Aiming to improve on these
treatment results, we designed a phase II study to evaluate
an intensive protocol including myeloablative treatment
in CNS recurrence of systemic B-cell non-Hodgkin’s
lymphoma (NHL). This study (HOVON 80, Netherlands
Trial Register, no. 1757) is an ongoing phase II study on
the feasibility and efﬁcacy of R-DHAP ? HD-MTX
(dexamethasone 40 mg days 1–4, cisplatin 100 mg/m
2
day 1, cytarabine 2 9 2 g/m
2 day 2, rituximab 375 mg/m
2
day 5, methotrexate 3 g/m
2 day 15), followed by autolo-
gous stem cell transplantation in patients with recurrent
aggressive B-cell lymphoma with CNS localization. Rit-
uximab is a chimeric anti-CD-20 antibody which has rad-
ically changed prospects for patients with systemic B-cell
lymphoma [3, 4]. However, after intravenous administra-
tion it does not penetrate the blood–brain barrier well, and
it has been postulated that intrathecal administration may
improve results of treatment of leptomeningeal lymphoma
[5, 6]. We therefore incorporated intrathecal rituximab into
the protocol.
The patients we report herein were all treated according
to protocol with systemic R-DHAP-MTX as described
above, for three 28-day cycles. Additionally, intrathecal
rituximab, containing no preservatives and without con-
current other agents, was administered via lumbar puncture
afterpremedicationwith paracetamol1,000 mgondays-1,
4, 8, 11, and 21 in the ﬁrst cycle, four times in the second
cycle, and three times in the third cycle. The ﬁrst adminis-
tration in each patient consisted of 10 mg rituximab; in
subsequent administrations the dose was increased to 25 mg
provided notoxicity hadoccurred.Thisdosingwasbasedon
prior publications [7, 8]. None of our patients experienced
side-effects after the ﬁrst intrathecal administration of rit-
uximab, except for a minor sensation of pressure in the
sacral area in one patient. However, after the ﬁrst adminis-
tration of 25 mg rituximab, 2 of the ﬁrst 12 treated patients
reported extremely painful paresthesia in the buttocks,
legs, and feet immediately after administration, lasting
30–60 min. There were no neurologic deﬁcits at the time,
nor on follow-up, but blood pressure increased temporarily.
After these adverse events the protocol was amended to
dilution of rituximab in 0.9% saline to 5 mg/ml and addi-
tional premedication with antihistamines. The subsequently
treated, 13th, patient suffered identical symptoms despite
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are given in Table 1. The pain resolved completely in all
patients within a few hours. However, they all refused fur-
ther treatment with intrathecal rituximab, and further
intrathecal therapy was changed to methotrexate, which was
administered uneventfully. The rituximab dose in the pro-
tocol was subsequently reduced to 10 mg per administra-
tion, diluted as described above and combined with 4 mg
intrathecal dexamethasone. Twelve additional patients were
thus treated, and no further incidents of painful radiculop-
athy have occurred.
In a phase I study investigating intraventricular/intra-
thecal rituximab, the maximum tolerated dose was found to
be 25 mg; at 50 mg, grade III hypertension was the dose-
limiting toxicity and one of two patients thus treated
additionally experienced transient diplopia, nausea, and
vomiting [7]. A painful radiculopathy was described after
intrathecal administration of 25 mg via lumbar puncture in
one patient; the majority, however, had been treated
intraventricularly. Antonini described one patient treated
with 40 mg intrathecal rituximab in whom transient head-
ache, cramps, back pain, and leg weakness occurred [9].
Schulz described six patients treated with 10–40 mg
undiluted intra-CSF rituximab for CNS lymphoma, two of
them via lumbar puncture; one of them suffered transient
severe back pain and paraparesis during the ﬁrst intrathecal
administration of rituximab (25 mg) [8]. In this patient a
high tumor load was present in the CSF and the authors
assumed a tumor lysis syndrome. However, in none of our
patients was high CSF cellularity present, making tumor
lysis an unlikely explanation.
Both acute and subacute toxicities have been observed
after intrathecal treatment with chemotherapeutic agents
[10–13]. For methotrexate as well as (sustained-release)
cytarabine an acute, reversible aseptic meningitis with
fever, headache, backache, nausea, and vomiting has been
described. Symptoms begin several hours after adminis-
tration and can be prevented with oral or intrathecal
dexamethasone in the majority of patients [10, 11]. An
inﬂammatory reaction is a likely cause for the aseptic
meningitis after methotrexate and cytarabine, but in
rituximab the occurrence during or immediately after
administration make an inﬂammatory reaction unlikely.
We postulate a direct interaction with spinal nervous
structures (radices?) as the most likely explanation for this
adverse reaction to rituximab.
This very painful, though completely transient, adverse
effect of intrathecal rituximab precludes intrathecal
administration of higher doses via lumbar puncture. It has
not been described after intraventricular administration,
despite the fact that considerably more patients have been
treated with rituximab via this route.
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